Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases, with an emphasis on hunger-associated conditions. Its wholly owned lead candidate, ARD-101, is an oral, gut-restricted… From the company’s description.
In fiscal 2025, Aardvark Therapeutics, Inc. reported a net loss of $57.59M. Operations used $54.17M in cash.
Dotted labels explain each measure. is shown separately from the annual figures.
What Aardvark Therapeutics, Inc. does
In the company’s own words
Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases, with an emphasis on hunger-associated conditions. Its wholly owned lead candidate, ARD-101, is an oral, gut-restricted bitter taste receptor (TAS2R) agonist designed to stimulate local release of satiety-related gut hormones; it is being developed for hyperphagia associated with Prader-Willi syndrome. The company’s second program, ARD-201, combines ARD-101 with a DPP-4 inhibitor and was planned for obesity and related conditions. Development of these programs’ clinical trials is paused while the company evaluates safety observations and discusses next steps with the FDA. Aardvark also conducts internal drug-discovery work to expand its pipeline across metabolic, inflammatory and adjacent indications. The company was founded in 2017, and its common stock began trading publicly following its February 2025 IPO. Its website is www.aardvarktherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1774857
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aardvark Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aardvark Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aardvark Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aardvark Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aardvark Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”